Ces radiol. 2026, 80(1):46-53 | DOI: 10.55095/CesRadiol2026/013

Distribution of 68Ga-PSMA-11 in tissues during prostate cancer imagingReview article

Martina Odvody, Marika Looseová, Eva Ferdová, Táňa Baráková, Jan Pernický, Jiří Ferda
Klinika zobrazovacích metod LF UK a FN, Plzeň
Korespondenční adresa:
Mgr. Martina Odvody
Klinika zobrazovacích metod LF UK A FN
alej Svobody 80, 323 00 Plzeň
Podpořeno projektem MZ ČR Koncepční rozvoj výzkumné instituce 00669806 - FN Plzeň a projektem COOPERATIO, basic sciences Univerzity Karlovy.
Konflikt zájmů: žádný.

Imaging of prostate cancer using the prostate-specific membrane antigen ligand 68Ga-PSMA-11 with positron emission tomography is currently the most important method for staging and restaging prostate cancer. This summary discusses the mechanisms of action of the radiopharmaceutical and the extent of the possible physiological distribution of 68Ga-PSMA-11.

Keywords: Key words: prostate cancer, 68Ga-PSMA-11, prostate-specific membrane antigen, positron emission tomography.

Accepted: February 15, 2026; Published: May 1, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Odvody M, Looseová M, Ferdová E, Baráková T, Pernický J, Ferda J. Distribution of 68Ga-PSMA-11 in tissues during prostate cancer imaging. Ces radiol. 2026;80(1):46-53. doi: 10.55095/CesRadiol2026/013.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lynge E, Andersen B, Bojesen SE, Petersen LK, Bech M, Bøgsted M, Dam MS, Egstrand S, Hvass AMF, Kobylecki CJ, Lång K, Nielsen M, Rossi GP, Stenger M, Vejborg I; Future of Cancer Screening Working Group. Challenges in the future of cancer screening. Int J Cancer 2026; 158(8): 2013-2022. doi: 10.1002/ijc.70286 [Epub 2025 Dec 16]. PMID: 41400247; PMCID: PMC12922640. Go to original source... Go to PubMed...
    2. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48(2): 326-334. doi: 10.1016/s0090-4295(96)00184-7. PMID: 8753752. Go to original source... Go to PubMed...
    3. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995; 62(5): 552-558. doi: 10.1002/ijc.2910620511. PMID: 7665226. Go to original source... Go to PubMed...
    4. Douglas TH, Connelly RR, McLeod DG, Erickson SJ, Barren R 3rd, Murphy GP. Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J Surg Oncol. 1995; 59(4): 246-250. doi: 10.1002/jso.2930590410. PMID: 7543173. Go to original source...
    5. Olsson CA, de Vries GM, Buttyan R, Katz AE. Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Urol Clin North Am. 1997; 24(2): 367-378. doi: 10.1016/s0094-0143(05)70383-9. PMID: 9126234. Go to original source... Go to PubMed...
    6. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012; 39(6): 1085-1086. doi: 10.1007/s00259-012-2069-0 [Epub 2012 Feb 4]. PMID: 22310854. Go to original source...
    7. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40(4): 486-495. doi: 10.1007/s00259-012-2298-2 [Epub 2012 Nov 24]. Erratum in: Eur J Nucl Med Mol Imaging 2013; 40(5): 797-798. PMID: 23179945. Go to original source... Go to PubMed...
    8. Afshar-Oromieh A, Haberkorn U, Hadaschik B, Habl G, Eder M, Eisenhut M, Schlemmer HP, Roethke MC. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging 2013; 40(10): 1629-1630. doi: 10.1007/s00259-013-2489-5 [Epub 2013 Jul 2]. PMID: 23817686. Go to original source... Go to PubMed...
    9. Ferda J, Hes O, Hora M, Ferdová E, Pernický J, Rudnev V, Pecen L, Topolčan O, Mírka H. Assessment of Prostate Carcinoma Aggressiveness: Relation to 68Ga- -PSMA-11-PET/MRI and Gleason Score. Anticancer Res. 2023; 43(1): 449-453. doi: 10.21873/anticanres.16181. PMID: 36585198. Go to original source... Go to PubMed...
    10. Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanawala S, Gambhir SS, Iagaru A. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga- -PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2016; 57(4): 557-562. doi: 10.2967/jnumed.115.168393 [Epub 2015 Dec 10]. PMID: 26659347. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content